<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370238</url>
  </required_header>
  <id_info>
    <org_study_id>REP0114</org_study_id>
    <secondary_id>2014-004796-23</secondary_id>
    <nct_id>NCT02370238</nct_id>
  </id_info>
  <brief_title>A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer</brief_title>
  <acronym>FRIDA</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé Farmaceutici S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dompé Farmaceutici S.p.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reparixin oral tablets are being tested as a CSC targeting agent in patients with metastatic
      non- human epidermal growth factor receptor (HER2)-amplified BC. An open label Phase 1b
      clinical study (REP0111) is ongoing (enrollment completed) in five US sites, under IND #
      112502, to test safety, tolerability, pharmacokinetics and detect early signs of antitumor
      activity of increasing doses of reparixin oral tablets in combination with a fixed dose of
      weekly paclitaxel. The study has demonstrated safety and tolerability of the combination
      across the three dose levels explored and recorded objective responses in the published range
      for single agent weekly paclitaxel in the target population. The highest dose level explored
      (i.e., 1200 mg t.i.d.) was identified as the recommended phase 2 dose. Durable responses have
      been recorded in patients with TNBC.

      The current phase 2 study thus aims to evaluate the Progression Free Survival of patients
      with metastatic TNBC [newly diagnosed metastatic or relapsed following (neo)adjuvant
      chemotherapy] receiving reparixin in combination with paclitaxel versus paclitaxel alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the cancer stem cell (CSC) model, tumors are initiated and maintained by a
      cellular subcomponent that displays stem cell properties. These properties include
      self-renewal, which drives tumorigenesis, and differentiation (albeit aberrant), which
      contributes to tumor cellular heterogeneity. The existence of CSCs has been described in a
      variety of haematologic and solid tumors including those of the breast, brain, colon,
      pancreas, lung, liver, and head and neck.

      In addition to driving tumorigenesis, CSCs may contribute to tumor metastasis as well as to
      tumor recurrence after treatment. Although currently available drugs can shrink metastatic
      tumors, these effects are usually transient and often do not appreciably extend the life of
      patients. One reason for the failure of these treatments is the acquisition of drug
      resistance by the cancer cells as they evolve; another non-mutually exclusive possibility is
      that existing therapies fail to kill CSCs. The ability to shrink a tumor mass mainly reflects
      an ability to kill bulk, non CSC tumor cells. This is because CSCs represent only a tiny
      percentage of the total tumor cells in a neoplastic lesion and the majority of the bulk tumor
      cells have limited proliferative potential. It seems that normal stem cells from various
      tissues tend to be more resistant to chemotherapeutics than mature cell types from the same
      tissues. The reasons for this are not clear, but may relate to high levels of expression of
      anti- apoptotic proteins or ATP-binding cassette (ABC) transporters such as the multidrug
      resistance gene. If the same were true of CSCs, then one would predict that these cells would
      be more resistant to chemotherapeutics than bulk tumor cells with limited proliferative
      potential. Even therapies that cause complete regression of tumors might spare enough CSCs to
      allow regrowth of the tumors. Thus, therapies that are more specifically directed against
      CSCs might result in much more durable responses and even cures of metastatic tumors.

      The CSC (Cancer stem cell) concept has important implications for understanding
      carcinogenesis as well as for the development of cancer therapeutics. According to this
      concept, tumors are initiated and maintained by a cellular subcomponent that displays stem
      cell properties. These properties include self-renewal, which drives tumorigenesis, and
      differentiation (albeit aberrant), which contributes to tumor cellular heterogeneity. The
      existence of CSCs has been described in a variety of hematologic and solid tumors including
      those of the breast, brain, colon, pancreas, lung, liver, and head and neck. In addition to
      driving tumorigenesis, CSCs may contribute to tumor metastasis as well as to tumor recurrence
      after treatment.

      One of the therapeutic strategies being pursued to target CSCs involves inhibition of self
      renewal or survival pathways in these cells. These pathways include NOTCH (Notch signaling
      pathway), Hedgehog, and WNT (Wnt signaling pathway). Such strategies may be limited by the
      role of these pathways in normal stem cell function, which could result in systemic
      toxicities from pathway inhibition. In addition to intrinsic pathways regulating stem cell
      functions, normal and malignant stem cells are regulated by extrinsic signals generated in
      the microenvironment or CSC niche. In the breast, this niche is composed of immune cells,
      mesenchymal elements that include fibroblasts, endothelial cells, adipocytes, and
      extracellular matrix components. These components play an important role in normal breast
      development and carcinogenesis. If the cellular microenvironment plays an important role in
      the regulation of CSC growth and survival, then strategies aimed at interfering with these
      interactions represent a rational approach to target breast CSCs.

      There are limited data on the impact of treatment tailoring based on CSCs detection. Gene
      profiling of CSCs could lead to identification of therapeutic targets on CSCs (e.g. hormone
      receptors, HER-2 [Human epidermal growth factor receptor-2] expression, EGFR [Epidermal
      growth factor receptor] expression), and could represent tumor biopsy in &quot;real time&quot;. Several
      groups showed frequent discordance of HER-2 status between primary tumor and CSCs, and case
      reports showed clinical utility to use of trastuzumab-based therapy based on HER-2 CSCs
      status. Similarly, the hormonal status of CSCs could be different from that of the primary
      tumor, which could lead to increase the number of patients suitable for endocrine therapy,
      but also could explain why endocrine therapy fails in a subset of hormone receptor-positive
      patients. The study provided the in vivo demonstration that CXCR-1 (Chemokine receptor 1)
      targeting with specific blocking antibodies or reparixin is associated with reduced systemic
      metastases. The experimental data provides another therapeutic target in metastatic disease
      and warrants a pilot study investigation in humans to further explore effects of reparixin on
      breast CSCs and the tumoral microenvironment.

      Reparixin seems to be a good candidate for use in breast cancer patients because of its very
      acceptable toxicity profile shown in the Phase I and II clinical trials conducted so far,
      along with its observed activity in vitro against breast cancer cell lines and in vivo in
      tumor xenografts in mice. It potentially addresses another therapeutic target in metastatic
      disease. The current phase 2 study thus aims to evaluate the Progression Free Survival of
      patients with metastatic TNBC [newly diagnosed metastatic or relapsed following (neo)adjuvant
      chemotherapy] receiving reparixin in combination with paclitaxel versus paclitaxel alone.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>Defined as the number of days between the date of randomization and the date of clinical disease progression (PD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median PFS (mPFS)</measure>
    <time_frame>18 months</time_frame>
    <description>Median PFS (mPFS) defined as the number of days between the date of randomization and the date of clinical disease progression (PD) according to RECIST criteria version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>18 months</time_frame>
    <description>Overall Survival defined as the interval (days) between randomization and death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>18 months</time_frame>
    <description>Objective response rates (ORR) defined as the percentage of the patients reaching complete remission (CR), partial remission (PR) or stable disease (SD) according to RECIST criteria version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>during 14 days before start of treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>Days 1, 8 and 15 of each cycle</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>Day 1 of each cycle</time_frame>
    <description>aspartate aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>Day 1 of each cycle</time_frame>
    <description>alanine aminotransferase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP</measure>
    <time_frame>Day 1 of each cycle</time_frame>
    <description>alkaline phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WBC</measure>
    <time_frame>Days 1, 8 and 15 of each cycle</time_frame>
    <description>White cells differential counts</description>
  </secondary_outcome>
  <other_outcome>
    <measure>TTM</measure>
    <time_frame>18 months</time_frame>
    <description>Median Time to new Metastasis (TTM)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel+reparixin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.
continuing from D 1 to Day 21 of 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel+placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)</description>
    <arm_group_label>paclitaxel+reparixin</arm_group_label>
    <arm_group_label>paclitaxel+placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reparixin</intervention_name>
    <description>reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle</description>
    <arm_group_label>paclitaxel+reparixin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle</description>
    <arm_group_label>paclitaxel+placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female aged ≥ 18 years.

          2. Patients with pathologically documented metastatic triple negative breast cancer
             (TNBC), eligible for treatment with paclitaxel. Paraffin-embedded tissue must be
             available from metastatic sites, if reasonably accessible, or from the primary tumor,
             to confirm the diagnosis of TNBC and for correlative studies (only on metastatic
             tissue). Fifteen slides can be obtained if the full block is not available to be sent
             or released.

             TNBC will be defined as breast cancer with &lt;1% ER+ and &lt;1% PgR+ cells, and HER2
             immunohistochemistry score of 0 or 1+ and/or in situ hybridization (ISH) with HER2
             gene copy number &lt;4 or a ratio of less than 2 between HER2 gene copy number and
             centromere of chromosome 17. Patients whose metastatic disease is TNBC are eligible
             even when their primary tumor expressed hormone receptors and/or HER2.

          3. Patients must be newly diagnosed metastatic or must have relapsed following a prior
             (neo)adjuvant chemotherapy regimen. If a taxane (i.e., paclitaxel or docetaxel) was
             administered as part of the (neo)adjuvant regimen, PD must have occurred &gt; 12 months
             from the end of previous (neo)adjuvant treatment. For non-taxane (neo)adjuvant
             regimen, PD must have occurred &gt; 6 months from the end of previous (neo)adjuvant
             treatment

          4. Patients with at least one baseline measurable lesion according to RECIST criteria
             version 1.1.

          5. Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0-1.

          6. Life expectancy of at least three months.

          7. Patients must be able to swallow and retain oral medication (intact tablet).

          8. Able to undergo all screening assessments outlined in the protocol.

          9. Adequate organ function (defined by the following parameters):

               1. Serum creatinine &lt; 140 μmol/L (&lt; 1.6 mg/dL) or creatinine clearance &gt; 60 mL/min.

               2. Serum hemoglobin ≥ 9 g/dL; absolute neutrophil count ≥ 1.5 x 109/L; platelets ≥
                  100 x 109/L.

               3. Serum bilirubin ≤ 1.5 x upper normal limit (UNL) except patients with Gilbert's
                  syndrome

               4. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 x
                  UNL but ≤ 5.0 x UNL in case of liver metastases; alkaline phosphatase (ALP) ≤ UNL
                  but i) ≤ 2.5 x UNL in case of liver metastases and ii) ≤ 5 UNL in case of bone
                  metastases; albumin ≥ 2.5 g/dl.

         10. No history or evidence by CT scan or MRI, of brain metastases or leptomeningeal
             disease.

         11. No known hepatitis B virus (not due to immunization), hepatitis C virus, human
             immunodeficiency virus-I and -II positive status.

         12. Dated and signed IEC/IRB-approved informed consent.

        Exclusion Criteria:

          1. Prior therapy for metastatic TNBC (chemotherapy, hormone therapy or biological
             therapy), Patients may receive bisphosphonates and other therapies to treat bone
             metastases, however if used, bone lesions will not be considered as measurable
             disease.

          2. Less than four weeks since last radiotherapy (excluding palliative radiotherapy).

          3. Pregnancy or lactation or unwillingness to use adequate method of birth control.

          4. Neurological or psychiatric disorders which may influence understanding of study and
             informed consent procedures.

          5. Active or uncontrolled infection.

          6. Malabsorption syndrome, disease significantly affecting gastrointestinal function.

          7. G&gt;1 pre-existing peripheral neuropathy

          8. Any other invasive malignancy from which the patient has been disease-free for less
             than 5 years with the exception of curatively treated basal or squamous cell skin
             cancer

          9. Hypersensitivity to:

               1. paclitaxel

               2. ibuprofen or to more than one non-steroidal anti-inflammatory drug.

               3. medications belonging to the class of sulfonamides, with the exception of
                  sulfanilamides (e.g., sulfamethoxazole).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dompé Milan</last_name>
    <role>Study Director</role>
    <affiliation>Dompé farmaceutici s.p.a. Milan Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dompé farmaceutici s.p.a. Milan</last_name>
    <email>cti.rep0114@dompe.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Meshad, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Meshad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CBCC Global Research a Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kanamori, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Kanamori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumithra Vattigunta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sumithra Vattigunta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumithra Vattigunta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sumithra Vattigunta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.-Georgia Cancer Specialists</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.-Georgia Cancer Specialists</name>
      <address>
        <city>Canton</city>
        <state>Georgia</state>
        <zip>30114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Conyers</city>
        <state>Georgia</state>
        <zip>30094</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.-Georgia Cancer Specialists</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelank, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Jonesboro</city>
        <state>Georgia</state>
        <zip>30236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.-Georgia Cancer Specialists</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.-Georgia Cancer Specialists</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Regional Medical Center</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Alvarez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.-Georgia Cancer Specialists</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia Zelnak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Covenant</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60625</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyse Lambiase, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elyse A Lambiase, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Illinois Hematology &amp; Oncology Associates, Ltd.</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Migas, MD</last_name>
    </contact>
    <investigator>
      <last_name>John Migas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Schott, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Schott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Papish, MD</last_name>
    </contact>
    <investigator>
      <last_name>Steven Papish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Sparta</city>
        <state>New Jersey</state>
        <zip>07871</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>May Abdo-Matkiwsky, MD</last_name>
    </contact>
    <investigator>
      <last_name>May Abdo-Matkiwsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates, PC</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Waverly Hematology Oncology</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Graham, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mark Graham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates of Northeast PA</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maysa Abu-Khalaf, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maysa Abu-Khalaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maysa Abu-Khalaf, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maysa Abu-Khalaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Goldstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lori Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Daniel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brooke Daniel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Chang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jenny Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Overlake Medical Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason C Comer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jason C Comer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Valley Hematology and Oncology, SC</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Conkright, MD</last_name>
    </contact>
    <investigator>
      <last_name>William Conkright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Klina</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Verhoeven, MD</last_name>
    </contact>
    <investigator>
      <last_name>Didier Verhoeven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint- LUC UCL</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Duhoux, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francois Duhoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manon Huizing, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manon Huizing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Richard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent Richard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ St Elisabeth</name>
      <address>
        <city>Namur</city>
        <zip>5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Henry, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphanie Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Masaryk Memorial Cancer Institute</name>
      <address>
        <city>Brno</city>
        <zip>65653</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Krasenska, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marta Krasenska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemocnice Horovice a.s.</name>
      <address>
        <city>Horovice</city>
        <zip>26831</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Smakal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Smakal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugen Kubala, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eugen Kubala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologická klinika VFN a 1.LF UK</name>
      <address>
        <city>Prague 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Zimovjanova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martina Zimovjanova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Brychta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Milan Brychta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice v Motole, Onkologická klinika 2. LF UK a FN Motol</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Prausová, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jana Prausová, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krajská nemocnice T.Bati, a. s.</name>
      <address>
        <city>Zlin</city>
        <zip>76275</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Kohoutek, MD</last_name>
    </contact>
    <investigator>
      <last_name>Milan Kohoutek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Campone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mario Campone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Levy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christelle Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de Saint-Brieuc, Yves Le Foll</name>
      <address>
        <city>La Roche sur Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Priou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frank Priou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) De Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Venat-Bouvet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence Venat-Bouvet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille cedex 9</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Goncalves, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Goncalves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Ferrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marc Ferrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris Cedex 15</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Medioni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jacques Medioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medicale Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Campone, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mario Campone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Di Summa-Perrino&quot;</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saverio Cinieri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Saverio Cinieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria</name>
      <address>
        <city>Cagliari</city>
        <zip>09042</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Scartozzi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mario Scartozzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria, Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Soto Parra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hector Soto Parra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dino Amadori, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dino Amadori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale dell'Angelo</name>
      <address>
        <city>Mestre</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Morandi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Morandi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Colleoni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Colleoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera, Ospedale San Carlo Borromeo</name>
      <address>
        <city>Milan</city>
        <zip>20153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Moroni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mauro Moroni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Pedrazzoli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Pedrazzoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Marche Nord</name>
      <address>
        <city>Pesaro</city>
        <zip>61122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamaria Baldelli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Annamaria Baldelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Biganzoli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laura Biganzoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Opspedaliero Universitaria Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Mansutti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mauro Mansutti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Giovanni e Paolo</name>
      <address>
        <city>Venezia</city>
        <zip>30122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Morandi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Morandi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bialostockie Centrum Onkologii im. Marii Sklodowskiej - Curie</name>
      <address>
        <city>Bialystok</city>
        <zip>15001</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Wojtukiewicz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marek Wojtukiewicz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wojewódzkie Centrum Onkologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80219</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Pikiel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joanna Pikiel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli</name>
      <address>
        <city>Lublin</city>
        <zip>20090</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bozena Kukielka-Budny, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bozena Kukielka-Budny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>61701</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Tomczak, MD</last_name>
    </contact>
    <investigator>
      <last_name>Piotr Tomczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mrukmed. Lekarz Beata Madej Mruk i Partner. Spólka Partnerska Oddzial nr 1 w Rzeszowie</name>
      <address>
        <city>Rzeszów</city>
        <zip>35085</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrzej Mruk, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrzej Mruk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magodent Sp. z o. o.</name>
      <address>
        <city>Warsaw</city>
        <zip>04125</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Sarosiek, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tomasz Sarosiek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico Regional de Galicia, Servicio de Oncologia Medica</name>
      <address>
        <city>La Coruña</city>
        <state>Galizia</state>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Ramos Vázquez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Ramos Vázquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Albanell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joan Albanell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Zamora, MD</last_name>
    </contact>
    <investigator>
      <last_name>Esther Zamora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario La Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Antolín, MD</last_name>
    </contact>
    <investigator>
      <last_name>Silvia Antolín, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Martin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-San Chinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estela Vega, MD</last_name>
    </contact>
    <investigator>
      <last_name>Estela Vega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>C. Hospital Xeral-Cies</name>
      <address>
        <city>Vigo</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isaura Fernandez Perez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isaura Fernandez Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.dompe.com</url>
    <description>Corporate webpage</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple negative metastatic breast cancer</keyword>
  <keyword>Cancer Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

